Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 8/14/2025

Sexually Transmitted Infections

Diagnostic Methods and Treatment Options

  • The Centers for Disease Control and Prevention (CDC) recommends testing to rule out other STIs, including Neisseria gonorrhoeae, Chlamydia trachomatis, and Mycoplasma genitalium, using validated nucleic acid amplification test (NAAT) on first-void urine or urethral smear 1, 2
  • Recommended treatment options for nongonococcal urethritis (NGU) include doxycycline 100 mg orally twice daily for 7 days, with high cure rates when both partners are treated simultaneously and adherence to the full 7-day course is maintained, as recommended by the European Urology guidelines and the CDC 2, 3, 4, 5
  • Alternative treatment options include azithromycin 1-1.5 g orally as a single dose, offering better compliance due to single-dose regimen and similar effectiveness to doxycycline in clinical trials, and may be preferred when compliance with multi-day regimens is a concern 4, 5, 2
  • Other treatment options include erythromycin 500 mg orally four times daily for 7 days, levofloxacin 500 mg orally once daily for 7 days, ofloxacin 300 mg orally twice daily for 7 days, and moxifloxacin 400 mg orally once daily for 7-14 days, for patients with allergies or resistant cases 3, 4, 2

Partner Management and Follow-up

  • The CDC recommends that all sexual partners within 60 days should be evaluated and treated, and simultaneous treatment of the patient's sexual partner, even without testing, is emphasized by the MMWR Recommendations and Reports to prevent reinfection 1, 3, 4, 5, 6
  • Partners who had sexual contact with the patient within 60 days prior to diagnosis should be tested and treated, and patients should abstain from sexual contact for at least 7 days after starting treatment and until symptoms have completely resolved 3, 4, 5
  • Abstinence from sexual activity is recommended until 7 days after treatment initiation and complete resolution of symptoms, and patient should return for evaluation if symptoms persist after treatment completion or symptoms recur after initial resolution 1

Special Populations

  • HIV-positive patients should receive the same treatment regimen as HIV-negative patients, according to the MMWR Recommendations and Reports, but immunocompromised patients, including those with HIV, may require more aggressive treatment and monitoring as severe disseminated infections can occur 4, 3, 4, 5
  • For adolescents, doxycycline is safe and appropriate, as concerns about dental staining primarily apply to children under 8 years, as recommended by the European Urology guidelines 7

Treatment Failure and Resistance

  • Patients with persistent symptoms after initial treatment should be retreated with the initial regimen if they did not adhere to the treatment or had contact with an untreated partner, as recommended by the MMWR Recommendations and Reports, and alternative treatment options include metronidazole 2 g orally in a single dose or tinidazole 2 g orally in a single dose, plus azithromycin 1 g orally in a single dose (if not used for initial episode) 3, 4, 5
  • Increasing resistance has been reported worldwide, with doxycycline maintaining the highest susceptibility rates, highlighting the importance of proper treatment and follow-up, and medication should ideally be provided in the clinic or healthcare provider's office to improve compliance, and failure to treat partners is a major cause of reinfection and treatment failure 2, 4, 5, 3, 2

Follow-up and Monitoring

  • No routine follow-up is needed if symptoms resolve, but patients should return for evaluation if symptoms persist or recur after completing therapy, as recommended by the MMWR Recommendations and Reports 3, 4, 5